PeptiMimesis Pharma
http://www.peptimimesis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PeptiMimesis Pharma
Merck KGaA's M Ventures Moving On Up With €600m Boost
The new capital will allow the VC arm to create and finance "a new and larger portfolio of innovative companies that align with the future strategies" of Merck's businesses.
Start-Up Previews, May 2016
In this month's issue of Start-Up, we profile 4Tech, Advanced Cooling Therapy, Enumeral Biomedical Holdings, MiNDERA, PeptiMimesis and Synchron.
PeptiMimesis
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice